.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Children with drug-resistant epilepsy may require non-pharmacological therapies when seizures remain uncontrolled despite multiple antiseizure medicines and surgery is not feasible. This randomized active-controlled paediatric trial evaluated high-output versus low-output vagus nerve stimulation in 41 children with intractable epilepsy. The study assessed seizure frequency, seizure severity and tolerability during a blinded treatment phase. High-output stimulation produced a greater reduction in seizure burden than the low-output control setting, supporting VNS as an adjunctive treatment in selected children. The study also showed why response should not be judged by a single seizure count: changes in seizure severity and overall clinical function can be relevant even when complete seizure freedom is not achieved. For HCPs, VNS should be considered within a multidisciplinary epilepsy programme that includes syndrome classification, surgical evaluation, developmental assessment and family counselling. The procedure does not remove the need for antiseizure medication, and response varies considerably between patients. Long-term benefit is generally assessed over months rather than days. The trial is particularly relevant to IANCON's emphasis on refractory epilepsy, paediatric epilepsy and neuromodulation.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Children with drug-resistant epilepsy may require non-pharmacological therapies when seizures remain uncontrolled despite multiple antiseizure medicines and surgery is not feasible. This randomized active-controlled paediatric trial evaluated high-output versus low-output vagus nerve stimulation in 41 children with intractable epilepsy. The study assessed seizure frequency, seizure severity and tolerability during a blinded treatment phase. High-output stimulation produced a greater reduction in seizure burden than the low-output control setting, supporting VNS as an adjunctive treatment in selected children. The study also showed why response should not be judged by a single seizure count: changes in seizure severity and overall clinical function can be relevant even when complete seizure freedom is not achieved. For HCPs, VNS should be considered within a multidisciplinary epilepsy programme that includes syndrome classification, surgical evaluation, developmental assessment and family counselling. The procedure does not remove the need for antiseizure medication, and response varies considerably between patients. Long-term benefit is generally assessed over months rather than days. The trial is particularly relevant to IANCON's emphasis on refractory epilepsy, paediatric epilepsy and neuromodulation.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
